First global estimates of economic costs of genital herpes infections

Genital herpes infections and their related complications lead to billions of dollars in health care expenditures and productivity losses globally, according to the first ever global estimates of the economic costs of these conditions.

The paper, which publishes July 1^st in the journal BMC Global and Public Health, calls for greater investment in prevention of herpes transmission, including concerted efforts to develop effective vaccines against this common virus.

Corresponding author Nathorn Chaiyakunapruk, PharmD, PhD, professor of pharmacotherapy, and Haeseon Lee, PharmD, research fellow in pharmacotherapy, both at the College of Pharmacy of University of Utah Health, performed the research in collaboration with the World Health Organization and other academic institutions. They detail the associated economic cost estimates for genital herpes globally and by region.

Herpes is caused by infection with one of two types of the herpes simplex virus (HSV). Around two thirds of people (67%) aged 0-49 globally have HSV-1, according to the latest published statistics. It is mostly acquired in childhood, spreads by oral contact and causes infections in or around the mouth (oral herpes or cold sores). Adults can acquire genital HSV-1 infection through sexual contact if they were not infected during childhood. Type 2 spreads by sexual contact and causes genital herpes. Approximately 13% of the world's population aged 15–49 years are living with HSV-2 infection.

In addition to sores and blisters, HSV can cause other more serious complications requiring healthcare attention, including a rare chance of mother-to-child transmission during childbirth, and increased risk of HIV infection.